Search research articles
Contact Us
Filters
Showing results (41-50 of 46) with videos related to
Page
of 5
Sort By:
You have reached the last page of results.
This site can display upto 46 results.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 22, 2022
Overall Survival With Daratumumab, Bortezomib, and Dexamethasone in Previously Treated Multiple Myeloma (CASTOR): A Randomized, Open-Label, Phase III Trial
Pieter Sonneveld, Asher Chanan-Khan, Katja Weisel, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation
|
October 29, 2017
Autologous/Allogeneic Hematopoietic Cell Transplantation versus Tandem Autologous Transplantation for Multiple Myeloma: Comparison of Long-Term Postrelapse Survival
Myo Htut, Anita D'Souza, Amrita Krishnan, et al.
Cancer
|
May 5, 2017
Hispanics have the lowest stem cell transplant utilization rate for autologous hematopoietic cell transplantation for multiple myeloma in the United States: A CIBMTR report
Jeffrey R Schriber, Parameswaran N Hari, Kwang Woo Ahn, et al.
Journal of Hematology & Oncology
|
August 22, 2020
Daratumumab, bortezomib, and dexamethasone in relapsed or refractory multiple myeloma: subgroup analysis of CASTOR based on cytogenetic risk
Katja Weisel, Andrew Spencer, Suzanne Lentzsch, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 16, 2015
Improved Outcomes After Autologous Hematopoietic Cell Transplantation for Light Chain Amyloidosis: A Center for International Blood and Marrow Transplant Research Study
Anita D'Souza, Angela Dispenzieri, Baldeep Wirk, et al.
Haematologica
|
September 22, 2018
Daratumumab plus bortezomib and dexamethasone <i>versus</i> bortezomib and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of CASTOR
Andrew Spencer, Suzanne Lentzsch, Katja Weisel, et al.
Page
of 5
Search research articles
Search
Showing results (41-50 of 46) with videos related to
Sort By:
Page
of 5
You have reached the last page of results.
This site can display upto 46 results.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 22, 2022
Overall Survival With Daratumumab, Bortezomib, and Dexamethasone in Previously Treated Multiple Myeloma (CASTOR): A Randomized, Open-Label, Phase III Trial
Pieter Sonneveld, Asher Chanan-Khan, Katja Weisel, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation
|
October 29, 2017
Autologous/Allogeneic Hematopoietic Cell Transplantation versus Tandem Autologous Transplantation for Multiple Myeloma: Comparison of Long-Term Postrelapse Survival
Myo Htut, Anita D'Souza, Amrita Krishnan, et al.
Cancer
|
May 5, 2017
Hispanics have the lowest stem cell transplant utilization rate for autologous hematopoietic cell transplantation for multiple myeloma in the United States: A CIBMTR report
Jeffrey R Schriber, Parameswaran N Hari, Kwang Woo Ahn, et al.
Journal of Hematology & Oncology
|
August 22, 2020
Daratumumab, bortezomib, and dexamethasone in relapsed or refractory multiple myeloma: subgroup analysis of CASTOR based on cytogenetic risk
Katja Weisel, Andrew Spencer, Suzanne Lentzsch, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 16, 2015
Improved Outcomes After Autologous Hematopoietic Cell Transplantation for Light Chain Amyloidosis: A Center for International Blood and Marrow Transplant Research Study
Anita D'Souza, Angela Dispenzieri, Baldeep Wirk, et al.
Haematologica
|
September 22, 2018
Daratumumab plus bortezomib and dexamethasone <i>versus</i> bortezomib and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of CASTOR
Andrew Spencer, Suzanne Lentzsch, Katja Weisel, et al.
Page
of 5